Antifibrotic Agents

03/05/2021 - "Antifibrotic agents can also be useful in the treatment of other types of progressivepulmonary fibrosis besides IPF. "
10/01/2005 - "We have investigated the Tsk1/+ mouse as a model system for testing the efficacy of antifibrotic agents against skin fibrosis. "
09/01/2023 - "This study aimed to identify novel anti-fibrotic agents using the TGF-β1-induced fibrosis in renal proximal tubule epithelial cells (RPTEC) and characterize their mechanism of action as well as in vivo efficacy. "
01/01/2021 - "This study highlights a complex interaction of cigarette smoking, advanced fibrosis of UIP, PH and potential utility of antifibrotic agents in CPFE phenotype. "
01/01/2017 - "Further study is needed to see if other anti-fibrotic agents may be useful in reversing lymphoid fibrosis and reducing HIV levels."

02/01/2018 - "Clinico-radiological features and efficacy of anti-fibrotic agents in atypical idiopathic pulmonary fibrosis."
01/01/2023 - "However, given the harm of immunosuppression in idiopathic pulmonary fibrosis, there is an urgent need for RCTs of immunosuppression and antifibrotic agents in fibrotic CTD-ILD populations as well as the study of intervention in patients with subclinical CTD-ILD."
04/10/2020 - "On the other hand, some similarities between RA-ILD and idiopathic pulmonary fibrosis and the results of the recent INBIULD trial suggest a possible future role for antifibrotic agents. "
01/01/2019 - "Antifibrotic agents are approved in idiopathic pulmonary fibrosis; studies with antifibrotics are underway for SSc-ILD. "
10/26/2023 - "Real-World Clinical Efficacy of Antifibrotic Agents for Idiopathic Pulmonary Fibrosis: A Single-Center Retrospective Study in Japan."

09/01/2023 - "Over the last decade, two anti-fibrotic agents have been shown to slow disease progression, however, both drugs are administered uniformly with minimal consideration of disease severity and inter-individual molecular, genetic, and genomic differences. "
06/08/2023 - "Treatment intervention including anti-fibrotic agents will be introduced in disease progression cases. "
01/01/2022 - "Although anti-fibrotic agents delay disease progression, they are not considered curative treatments, and alternative modalities have attracted attention. "
01/01/2022 - "Antifibrotic agents can slow but not stop disease progression in patients with IPF or PF-ILD. "
12/01/2021 - "Treatment with antifibrotic agents can slow, but not halt, disease progression, and treatment discontinuation because of adverse events is common. "

03/01/2017 - "In this regard, continued efforts have been made to develop better treatments for underlying liver diseases and antifibrotic agents in multiple clinical and therapeutic trials; the best results may be expected with the integration of such evidence. "
01/01/2019 - "Sophisticated animal models are needed to investigate novel treatment options for different etiologies of liver disease, effective anti-fibrotic agents as well as vasoactive drugs against PHT. "
12/01/2016 - "This has led to numerous clinical trials of antifibrotic agents in patients with chronic liver disease. "
04/01/2015 - "We believe this animal model is ideal to study usefulness of antifibrotic agents in cholestatic liver disease because of the similarity in genetics and hepatic histopathology to human cholestatic liver disease."
03/14/2014 - "Anti-fibrotic agents presage a new era of supplemental treatment for chronic liver disease. "

01/01/2016 - "Blebs and bleb associated complications are catastrophic side effects of anti-fibrotic agents, which occasionally are encountered in a subset of patients. "
06/01/2006 - "We describe methods and outcomes of surgical reduction of symptomatic, circumferential, filtering blebs after trabeculectomy with antifibrotic agents. "
02/01/2005 - "To characterize and compare the histological features of conjunctiva obtained during the repair of trabeculectomy and inadvertent blebs and to assess the effects of antifibrotic agents. "
01/01/2019 - "It does not necessitate the use of any antifibrotic agents and results in safe and effective IOP reductions in patients with open-angle glaucoma (OAG) with minimal complications and no bleb-related adverse events. "
08/01/1999 - "Antifibrotic agents are not associated with a higher risk for late-onset, bleb-associated endophthalmitis. "